fashion -WSS

fashion

author：leisure time 2025-09-29 16:21:17 - browse：8

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： eGenesis tests gene

hotspot

WSS

Francis Collins on trust in science and how Covid communications failed

This gene therapy has record $4.25 million price. It's saved children.

Bring on the sabbaticals for nurses

Yancopoulos of Regeneron works to expand Dupixent success

Parkinson’s finding may lead to tests and, someday, treatments

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Guidelines to prevent youth baseball injuries need more muscle

Biotech venture capitalists face new demands from investors

The high cost of giving birth even with insurance

The tragedy of Johnson & Johnson’s Covid vaccine

Medical leaders decry Supreme Court decision on affirmative action

Elizabeth Holmes banned from government health programs

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare Advantage insurers pressure Biden for bigger payments

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

focus

Medicare Advantage insurers pressure Biden for bigger payments

'Patient friction coefficient' can gauge a clinical trial's patient burden

Chinese researcher claims birth of first gene

Medicare Advantage today, explained in one chart

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Test for long Covid? Researchers find new clue in blood samples

focus

knowledge

hotspot

explore